Unknown effects from extended or repeated use cannot be ruled out
The information search was conducted in Spanish and English, and the following keywords were used: steatosis, non-alcoholic fatty liver disease, drugs, treatment, fibrosis, MASH, NASH, MASLD, resmetirom, and GLP-1. Publications from 2010 to July 2025 were included

To accelerate progress in manufactured islet cell therapies, the panelists agreed that the top priorities are: More companies exploring novel approaches Expanding eligibility criteria for trialsand incoporating the perspectives of the T1D community into regulatory decisionsso we can build more evidence around the safety and efficacy of manufactured islet cell therapies Additional frameworks to help guide the field, like our cell therapies roadmap and upcoming publications from Breakthrough T1D staff around manufacturing and preclinical considerations Optimizing manufacturing processes to reduce costs and ensure access for people who want these therapies Optimizing cell therapy products by reducing or eliminating the need for immunosuppression and finding the best transplant site for survival Brynn Marks, M.D., Senior Director of Medical Affairs, chaired a session about the promise and perspective of islet cell replacement therapies for kids with T1D

It even asks for your most recent blood pressure reading